3 citations
,
May 2008 in “Journal of Clinical Oncology” This study found that Pmab treatment may alter hair follicle growth cycles, leading to trichomegaly and hypertrichosis, but these effects do not correlate with other skin toxicities.
51 citations
,
May 2013 in “The Journal of Steroid Biochemistry and Molecular Biology” This review examines the role of steroidal inhibitors in treating prostatic diseases but presents no new clinical results.
9 citations
,
November 2018 in “Acta Clinica Belgica” This case report suggests that spironolactone may induce prostate cancer proliferation in patients on abiraterone acetate, advising against its use for managing treatment-associated side effects in these individuals.
August 2023 in “Frontiers in Oncology” This review highlights recent advancements in prostate cancer treatments, particularly new drugs targeting signaling pathways and showing promise in clinical trials, but notes the high recurrence rate of castration-resistant cancer post-therapy, requiring ongoing efforts for effective solutions.
June 2024 in “ESMO Gastrointestinal Oncology” The BAYONET trial is a phase II study designed to assess the efficacy and safety of combining encorafenib, binimetinib, and cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer that is resistant to encorafenib plus cetuximab; results are not yet reported.
March 2026 in “Journal of Cancer Survivorship” This review highlights the potential for physical exercise to reduce treatment toxicity and modification rates in patients with metastatic colorectal cancer receiving systemic treatments, suggesting benefits for survival outcomes; it recommends further trials to confirm these findings.
36 citations
,
July 2022 in “Journal of Medicinal Chemistry” This review discusses various compounds targeting the androgen receptor, including recent developments in heterobifunctional degraders for prostate cancer treatment, but reports no new clinical results.
4 citations
,
August 2017 in “Journal of cutaneous pathology” This case report documents only the second known instance of congenital lymphadenoma, expanding the diagnostic possibilities for cutaneous lymphoepithelial tumors in children.
35 citations
,
January 2004 in “European journal of oncology nursing” In patients undergoing treatment with capecitabine for colon cancer and metastatic breast cancer, this study observed that hand-foot syndrome occurred more frequently than with intravenous 5-FU, but other side effects were less common.
May 2019 in “Paediatrics and child health” This review discusses diagnosis and management strategies for polycystic ovary syndrome in teenagers and reports no new clinical findings, emphasizing tailored approaches considering symptoms, psychological well-being, and fertility needs.
25 citations
,
June 2019 in “Endocrine Related Cancer” This review discusses the structure and function of steroid nuclear receptors, particularly focusing on androgen receptor dysregulation in prostate cancer and androgen insensitivity syndromes, without reporting new experimental results.
21 citations
,
January 2021 in “Therapeutic Advances in Endocrinology and Metabolism” The researchers suggest that testosterone levels might influence COVID-19 susceptibility and severity, with low levels potentially protecting against infection but possibly worsening severe disease due to cytokine storm activation.
10 citations
,
May 2018 in “Neuropharmacology” This study suggests that inhibitors of steroidogenic enzymes may have therapeutic potential for certain behavioral disorders linked to dopaminergic hyperfunction, despite concerns about their endocrine impacts.
5 citations
,
January 2022 in “Clinical cancer investigation journal” This study suggests that certain Dibenzo derivatives may be promising candidates for prostate cancer treatment due to their potential interactions with the androgen receptor and 5α-reductase enzyme.
June 2023 in “SPIRE - Sciences Po Institutional REpository” This study suggests that extracellular vesicles from prostate cancer cells could aid in identifying tumor heterogeneity and serve as biomarkers, while also playing a role in SARS-CoV-2 infection in nasopharyngeal mucus.
January 2022 in “Asian journal of Current Research in Clinical Cancer” This study reviews the potential of dibenzo derivatives as safer cancer treatments but finds conflicting evidence about their effectiveness, possibly due to structural differences among the compounds, and reports no new results.
December 2016 in “University of Birmingham Institutional Research Archive (University of Birmingham)” This study suggests that the adrenal gland may contribute to prostate cancer treatment resistance and indicates potential steroid production or dependency in ovarian cancer.
106 citations
,
April 2010 in “ACS Nano” This study found that about 80% of known fullerene-binding proteins rank in the top 10% of scorers for C60 docking sites, confirming the accuracy of the predictive model used.
38 citations
,
February 2012 in “Supportive Care in Cancer” Skin problems like acne, dry skin, and nail and hair changes are common in patients taking EGFR inhibitors.
30 citations
,
August 2010 in “American Journal of Clinical Dermatology” This article reviews eyelash elongation as a side effect of EGFR inhibitors in cancer treatment, finding that the condition is typically not severe and may be managed by trimming.
24 citations
,
May 2012 in “International Journal of Dermatology” This review discusses the various causes and associations of eyelash trichomegaly, including congenital syndromes, acquired conditions, and drug effects, without reporting new clinical results.
14 citations
,
June 2021 in “Expert Opinion on Therapeutic Patents” This review discusses various Wnt pathway modulators developed between 2014 and 2020, highlighting their potential as treatments for diseases like cancer and osteoarthritis, but reports no new clinical results.
November 2022 in “CARDIOMETRY” This article discusses the potential benefits of GcMAF and oral MAF, developed by "Saisei Mirai", for cancer and other conditions, but reports no new clinical results.
37 citations
,
June 2004 in “Human molecular genetics online/Human molecular genetics” This study suggests that the HCR risk allele within the PSORS1 locus may contribute to psoriasis susceptibility by altering gene expression related to skin structure and differentiation, although these changes alone might not result in clinical symptoms.
38 citations
,
December 2009 in “Therapeutic Advances in Medical Oncology” This discussion proposes a model to incorporate patients with hormone-resistant prostate cancer into the existing framework by redefining hormone resistance and exploring new therapeutic approaches.
1 citations
,
December 2018 in “Journal of genetic medicine” In this case report, a 20-year-old male with tricho-rhino-phalangeal syndrome was found to have a de novo frameshift mutation in the TRPS1 gene, highlighting the challenges in diagnosing this rare disorder.
1 citations
,
February 2023 in “Pediatric Dermatology” This case report of an infant with IPEX syndrome highlights the importance of early recognition and treatment, as the patient experienced severe symptoms and succumbed before stem cell transplantation.
June 2025 in “Albus Scientia” This review discusses the role of the MC1R gene in human pigmentation and its genetic variants, reporting no new results; the authors highlight its forensic applications for phenotypic prediction.
April 2023 in “Journal of Investigative Dermatology” In this retrospective cohort study, 53.8% of adult rosacea patients who started CGRP monoclonal antibodies for migraines experienced improvement in papules/pustules and erythema/flushing, although moderate adverse events were noted, suggesting these antibodies may benefit rosacea symptoms.
12 citations
,
August 2019 in “BMC Medical Genetics” This study found that two MC4R gene polymorphisms are associated with higher BMI in women with PCOS in western Saudi Arabia, but are not linked to PCOS itself.